title: Course of depressive symptoms over follow-up. Findings from the National Institute of Mental Health Treatment of Depression Collaborative Research Program.
abstract: We studied the course of depressive symptoms during an 18-month naturalistic follow-up period for outpatients with Major Depressive Disorder treated in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. The treatment phase consisted of 16 weeks of randomly assigned treatment with the following: cognitive behavior therapy, interpersonal therapy, imipramine hydrochloride plus clinical management (CM), or placebo plus CM. Follow-up assessments were conducted at 6, 12, and 18 months after treatment. Of all patients entering treatment and having follow-up data, the percent who recovered (8 weeks of minimal or no symptoms following the end of treatment) and remained well during follow-up (no Major Depressive Disorder relapse) did not differ significantly among the four treatments: 30% (14/46) for those in the cognitive behavior therapy group, 26% (14/53) for those in the interpersonal therapy group, 19% (9/48) for those in the imipramine plus CM group, and 20% (10/51) for those in the placebo plus CM group. Among patients who had recovered, rates of Major Depressive Disorder relapse were 36% (8/22) for those in the cognitive behavior therapy group, 33% (7/21) for those in the interpersonal therapy group, 50% (9/18) for those in the imipramine plus CM group, and 33% (5/15) for those in the placebo plus CM group. The major finding of this study is that 16 weeks of these specific forms of treatment is insufficient for most patients to achieve full recovery and lasting remission. Future research should be directed at improving success rates of initial and maintenance treatments for depression.
authors.affiliation: Department of Psychiatry and Human Behavior, Brown University, Providence, RI 02906.
authors.forename: M T
authors.initials: MT
authors.lastname: Shea
authors.forename: I
authors.initials: I
authors.lastname: Elkin
authors.forename: S D
authors.initials: SD
authors.lastname: Imber
authors.forename: S M
authors.initials: SM
authors.lastname: Sotsky
authors.forename: J T
authors.initials: JT
authors.lastname: Watkins
authors.forename: J F
authors.initials: JF
authors.lastname: Collins
authors.forename: P A
authors.initials: PA
authors.lastname: Pilkonis
authors.forename: E
authors.initials: E
authors.lastname: Beckham
authors.forename: D R
authors.initials: DR
authors.lastname: Glass
authors.forename: R T
authors.initials: RT
authors.lastname: Dolan
mesh_terms: D000328:Adult; D000553:Ambulatory Care; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D003866:Depressive Disorder / Q000188:drug therapy / Q000523:psychology / Q000628:therapy*; D005500:Follow-Up Studies; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use*; D008875:Middle Aged; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D011613:Psychotherapy; D012008:Recurrence; D012189:Retrospective Studies
chemical_list: D010919:Placebos; D007099:Imipramine